GOG-0252

Terminated

Return to Protocol Table

A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865, IND #7921)

Principal Investigator

Joan Walker

Status

Terminated

Closed to Accrual

November 30, 2011

Closed to Accrual & Treatment

November 30, 2011

Closed to Accrual & Treatment

May 18, 2013

Complete

March 12, 2021

Terminated

March 12, 2021

Terminated

March 12, 2020


Disease Site

Gynecologic [GY] Ovarian

Phase

III

Developmental Therapeutics

No

Primary Objective

To determine if one or both of the proposed intraperitoneal chemotherapy regimens improves the progression-free survival (PFS) event rate compared to standard intravenous chemotherapy for first-line treatment of patients diagnosed with advanced stage ovarian, peritoneal or fallopian tube cancer. 

Patient Population

Patients diagnosed with advanced stage ovarian, peritoneal or fallopian tube cancer. 

Target Accrual

1500

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.